Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,781 total articles

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apr 16, 2026
Priya Menon
Press Releases

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Revolution Medicines, a Nasdaq-listed late-stage clinical oncology company specializing in RAS-addicted cancer therapies, completed concurrent upsized public offerings of common stock and convertible senior notes totaling approximately $2.2 billion. The net proceeds will be utilized to support research and development, potential commercialization, …

RVMD
Hingham Savings Reports First Quarter 2026 Results
Apr 16, 2026
Maya Rios
Press Releases

Hingham Savings Reports First Quarter 2026 Results

Hingham Institution for Savings reported first quarter 2026 earnings showing a 60.2% decrease in GAAP net income per share compared to last year, primarily due to a net loss on equity securities. However, Core net income, excluding equity securities gains/losses, rose 72.3%. Total assets grew slightly to $4.55 billion with retail and commercial dep…

HIFS
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Apr 16, 2026
Caleb Monroe
Press Releases

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Oncology announced compelling preclinical data for its breast cancer therapies palazestrant and OP-3136 at the 2026 AACR Annual Meeting. Palazestrant, a complete estrogen receptor antagonist and degrader, demonstrated robust anti-tumor activity by recruiting corepressor NCoR1 to fully block estrogen receptor activity. Combined with OP-3136, a…

OLMA
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Apr 16, 2026
Jordan Park
Press Releases

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology presented preclinical data demonstrating that its oral PLK1 inhibitor, onvansertib, combined with trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, shows robust antitumor activity and overcomes resistance in HER2-low breast cancer models. The combination produced high tumor regression rates and good tolerabil…

CRDF
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Apr 16, 2026
Maya Rios
Press Releases

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio Therapeutics announced new preclinical data for XTX601, a masked T cell engager aimed at selectively targeting the tumor-associated antigen CLDN18.2 in gastric, pancreatic, and esophageal cancers. The data demonstrated tumor-selective activation, potent anti-tumor activity in multiple models, and a favorable safety profile in non-human primat…

XLO
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Apr 16, 2026
Nina Shah
Press Releases

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics announced preclinical findings demonstrating strong synergistic effects of its lead cancer drug candidates ACR-368 and ACR-2316 when combined with anti-PD-L1 immune checkpoint inhibitors and antibody-drug conjugate (ADC) payloads, specifically Topoisomerase 1 inhibitors. These results support the potential for developing frontl…

ACRV
Zhihu Inc. Publishes 2025 Environmental, Social and Governance Report
Apr 16, 2026
Sofia Navarro
Press Releases

Zhihu Inc. Publishes 2025 Environmental, Social and Governance Report

Zhihu Inc., a leading Chinese online content community listed on NYSE (ZH) and HKEX (2390), has published its 2025 Environmental, Social, and Governance Report. The Report details Zhihu's sustainability efforts, corporate culture development, and commitment to creating long-term value for stakeholders. The document is accessible in both English and…

ZH
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
Apr 16, 2026
Maya Rios
Press Releases

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Repligen Corporation has inaugurated its third global Training & Innovation Center in Breda, Netherlands, expanding its global customer support network. The new center at the OPUS pre-packed chromatography columns manufacturing facility offers hands-on experiences with Repligen's diverse bioprocessing technologies. This expansion complements existi…

RGEN
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Apr 16, 2026
Avery Klein
Press Releases

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Ltd. has submitted an Orphan Drug Designation application to the FDA for SkinJect®, a localized treatment for basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic disorder causing frequent skin cancers. The move targets a high unmet medical need with no approved therapies, aiming to offer a repeatable, non-surgical o…

MDCX
PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing Companies
Apr 16, 2026
Derek Hwang
Press Releases

PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing Companies

PMGC Holdings, Inc. announced a $40 million equity purchase facility agreement with an institutional investor, providing flexible capital to support its roll-up strategy targeting U.S.-based precision manufacturing companies in aerospace, defense, and industrial sectors. The company aims to grow through acquisitions and operational investments, cap…

ELAB
Lincoln Educational Services Corporation Schedules First Quarter 2026 Earnings Release And Conference Call
Apr 16, 2026
Ajmal Hussain
Press Releases

Lincoln Educational Services Corporation Schedules First Quarter 2026 Earnings Release And Conference Call

Lincoln Educational Services Corporation announced the date and details for its first quarter 2026 earnings release and conference call, scheduled for May 11, 2026. The company will provide a webcast and teleconference access to discuss its financial results and business updates. Lincoln is a leading provider of career-oriented post-secondary educa…

LINC
BGIN BLOCKCHAIN LIMITED Schedules the Fiscal Year 2025 Earnings and Conference Call on April 24, 2026
Apr 16, 2026
Sofia Navarro
Press Releases

BGIN BLOCKCHAIN LIMITED Schedules the Fiscal Year 2025 Earnings and Conference Call on April 24, 2026

BGIN BLOCKCHAIN LIMITED, a Nasdaq-listed digital asset technology company specializing in proprietary cryptocurrency mining technologies and hardware manufacturing, announced the date and details of its Fiscal Year 2025 earnings conference call to be held on April 24, 2026. Management will discuss financial results and strategic developments relati…

BGIN
CTW Cayman to Hold Annual General Meeting on May 7, 2026: Shareholders to Vote on Corporate Name Change and Amended Articles
Apr 16, 2026
Jordan Park
Press Releases

CTW Cayman to Hold Annual General Meeting on May 7, 2026: Shareholders to Vote on Corporate Name Change and Amended Articles

CTW Cayman announced an Annual General Meeting to be held on May 7, 2026, where shareholders will vote on proposals including changing the corporate name to CTW, adopting the second amended and restated memorandum and articles of association, and related actions. The Board recommends shareholders vote in favor of all proposals. CTW operates a leadi…

CTW
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
Apr 16, 2026
Ajmal Hussain
Press Releases

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

Alterity Therapeutics has appointed Ann Cunningham, a seasoned biotech and pharmaceutical executive with over 25 years' experience, to its Board of Directors. This strategic move comes as the company prepares to advance its lead candidate ATH434 into Phase 3 trials for Multiple System Atrophy (MSA), highlighting confidence in its late-stage develop…

ATHE
Sysco Declares Increase to Quarterly Dividend Payment
Apr 16, 2026
Nina Shah
Press Releases

Sysco Declares Increase to Quarterly Dividend Payment

Sysco Corporation's Board of Directors declared a quarterly cash dividend increase of $0.01 to $0.55 per share, payable July 24, 2026. This dividend raise highlights Sysco's strong shareholder return strategy and its status as a Dividend Aristocrat. The company plans a total annual dividend increase of $0.04 for fiscal year 2027, reinforcing its ba…

SYY
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
Apr 16, 2026
Derek Hwang
Press Releases

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

Lyra Therapeutics announced its intention to voluntarily file Form 25 to delist its common stock from Nasdaq following suspension of trading in March 2026. The company plans to deregister its stock by filing Form 15 to terminate reporting obligations with the SEC, continuing its shares' quotation on the Pink Limited Market.

LYRA
Commerce Announces Winners of EMEA Region Customer and Partner Awards Recognizing Innovation and Meaningful Results in Ecommerce
Apr 16, 2026
Derek Hwang
Press Releases

Commerce Announces Winners of EMEA Region Customer and Partner Awards Recognizing Innovation and Meaningful Results in Ecommerce

Commerce (NASDAQ: CMRC), the parent company of BigCommerce and Feedonomics, announced winners of its 2026 EMEA Customer and Partner Awards recognizing outstanding innovation, growth, and digital transformation achievements. The awards highlight significant advancements in AI-driven commerce, connected customer experiences, and B2B ecommerce excelle…

CMRC
zSpace Announces 1-for-25 Reverse Stock Split
Apr 16, 2026
Hana Yamamoto
Press Releases

zSpace Announces 1-for-25 Reverse Stock Split

zSpace, Inc., a Nasdaq-listed AR/VR solutions provider for education and workforce development, announced a 1-for-25 reverse stock split to increase its per-share stock price and regain compliance with Nasdaq's minimum bid price rule. The split will reduce outstanding shares from approximately 76 million to 3 million, with trading on Nasdaq continu…

ZSPC
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Apr 16, 2026
Avery Klein
Press Releases

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Boundless Bio announced preclinical data supporting its lead ecDNA-directed therapy candidate, BBI-940, a novel oral kinesin degrader targeting ecDNA segregation in cancer cells. The therapy demonstrated potent antitumor activity in breast cancer models, including ER+/HER2- and TNBC-LAR subtypes, and is currently being evaluated in a Phase 1 clinic…

BOLD